Clinical trials: sponsored by Almirall, S.A.
Atopic Dermatitis
A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis
The main aim of the study is to evaluate the efficacy and safety of lebrikizumab treatment for up to 32 weeks in participants with moderate-to-severe face and neck atopic dermatitis (FNAD) who also have moderate-to-severe AD…
- Trial name
- ADface (NCT07873801)
- Testing
- Lebrikizumab
- Volunteers
- 230 people
- Sponsor
- Almirall, S.A.
Atopic Dermatitis (AD)
The Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis
The purpose of this study is to understand cellular and molecular interactions in the skin of participants with mild-to-moderate AD, and how botulinum toxin alters these interactions.
- Trial name
- AD (NCT06928246)
- Testing
- Onabotulinum Toxin Type A - Phase 1b, Onabotulinum Toxin Type A - Phase 2
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Daniel Kaplan
Atopic Dermatitis
Lebrikizumab in Moderate-to-severe Atopic Dermatitis
This research is studying a drug already approved for the treatment of atopic dermatitis (AD). This research collects health-related information and blood and skin samples to understand if the study drug, lebrikizumab, leads to…
- Trial name
- ADfind (NCT06906497)
- Testing
- lebrikizumab
- Where
- 4 sites in United States, Germany and 1 more
- Volunteers
- 48 people
- Sponsor
- Johann E Gudjonsson MD PhD
Nummular Eczema
A Study of Lebrikizumab in Adults With Nummular Eczema
The main aim of the study is to evaluate the efficacy, safety, and tolerability of lebrikizumab treatment in adult participants with Nummular Eczema (NE) who are not adequately controlled with Topical corticosteroids (TCS) or…
- Trial name
- LUMINE (NCT07542483)
- Testing
- Lebrikizumab
- Where
- Germany
- Volunteers
- 270 people
- Sponsor
- Almirall, S.A.
Hidradenitis Suppurativa
A Proof-of-Concept Study of LAD328 in Adults With Hidradenitis Suppurativa
The main purpose of this study is to evaluate the effect of LAD328 compared to placebo in participants with moderate-to-severe Hidradenitis Suppurativa (HS), and to access the safety, tolerability, pharmacokinetic and…
- Trial name
- NCT07547813
- Testing
- LAD328
- Where
- Poland
- Volunteers
- 50 people
- Sponsor
- Almirall, S.A.
Atopic Dermatitis, Eczema
Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis
The main purpose of this study is to evaluate the effectiveness of 24 weeks of lebrikizumab in improving disease severity, signs, and symptoms in adults and adolescents with moderate-to-severe atopic dermatitis (AD).
- Trial name
- ADhope (NCT05990725)
- Testing
- Lebrikizumab
- Where
- 33 sites in Germany, Netherlands and 1 more
- Volunteers
- 260 people
- Sponsor
- Almirall, S.A.
Keratosis, Actinic
A Study to Evaluate the Efficacy and Safety of Tirbanibulin Ointment in Adult Participants With Actinic Keratosis
The purpose of the study is to evaluate the efficacy and safety of tirbanibulin 10 milligrams per gram (mg/g) ointment when applied to a treatment field (TF) larger than 25 square centimeters (cm^2) and up to 100 cm^2 in adult…
- Trial name
- TirbAKare (NCT06135415)
- Testing
- Tirbanibulin, Vehicle ointment
- Where
- 35 sites in Germany, Italy and 3 more
- Volunteers
- 280 people
- Sponsor
- Almirall, S.A.
Atopic Dermatosis, Alloknesie
Study of Alloknesia in Atopic Dermatitis
Alloknesia is defined as pruritus (= itching) triggered by light mechanical stimuli, which are responsible for the perception of light touch under physiological conditions, but which are perceived as pruritic under pathological…
- Trial name
- ALLOKNESIE (NCT06923202)
- Where
- 8 sites in France
- Volunteers
- 160 people
- Sponsor
- University Hospital, Brest
Alopecia Areata
A Study of LAD603 in Adults With Alopecia Areata
The main aim of the study is to evaluate the effect of LAD603 in adult participants with severe to very severe alopecia areata (AA).
- Trial name
- NCT07311564
- Testing
- LAD603
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- Almirall, S.A.
Healthy Volunteers
A Study of LAD106 in Healthy Adult Participants
The main aim of this study is to assess the safety, tolerability, pharmacokinetics (PK), immunogenicity and pharmacodynamics (PD) of single ascending doses of LAD106 (Part A) and multiple ascending doses of LAD106 (Part B) in…
- Trial name
- NCT07471932
- Testing
- LAD106, Lebrikizumab
- Where
- Netherlands
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- Almirall, S.A.
Atopic Dermatitis
Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participant With Moderate-to-Severe Atopic Dermatitis
The main purpose of the study is to assess the long-term tolerability and effectiveness of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD).
- Trial name
- ADlong (NCT05916365)
- Testing
- Lebrikizumab
- Where
- 32 sites in Germany, Poland
- Volunteers
- 174 people
- Sponsor
- Almirall, S.A.
Hidradenitis Suppurativa
A Study of LAD191 in Adults With Hidradenitis Suppurativa
The main purpose of this study is to assess the efficacy of multiple dosing regimens of LAD191 compared to placebo in participants with moderate-to-severe Hidradenitis Suppurativa (HS) and to access the safety, tolerability…
- Trial name
- NCT07151937
- Testing
- LAD191, Adalimumab
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- Almirall, S.A.
Acne Vulgaris
Comparing Sarecycline and Doxycycline Effects on the Skin and Gut Bacteria in Acne.
This study is being done to help better understand how the gut and skin bacteria of the body change when people with acne are treated with Sarecycline or Doxycycline.
- Trial name
- NCT07544251
- Testing
- Sarecycline, Doxycycline
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Integrative Skin Science and Research
Dermatitis, Atopic, Eczema
A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis
The main purpose of this study is to evaluate the effectiveness of 24 weeks of lebrikizumab in improving disease severity, signs, and symptoms in adults and adolescents with moderate-to-severe AD in Part 1 and to describe how…
- Trial name
- ADhope 2 (NCT06526182)
- Testing
- Lebrikizumab
- Where
- 4 sites in Spain
- Volunteers
- 520 people
- Sponsor
- Almirall, S.A.
Plaque Psoriasis
Observational Study of Tildrakizumab in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice
The observational, non-interventional study will assess the efficacy, safety, prescription and utilization patterns of Tildrakizumab in participants with moderate to severe plaque psoriasis in routine clinical practice.
- Trial name
- SAIL (NCT04203693)
- Testing
- Tildrakizumab
- Where
- 41 sites in Austria, Belgium and 4 more
- Volunteers
- 331 people
- Sponsor
- Almirall, S.A.
Healthy Volunteers
A Single and Multiple Ascending Dose Study of LAD603 in Healthy Subjects
The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of single and multiple ascending doses of LAD603 in healthy adult participants in both Part 1 and 2.
- Trial name
- NCT06200597
- Testing
- LAD603
- Where
- United States
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Almirall, S.A.
Healthy Volunteers, Autoimmune Disease
Single and Multiple Ascending Dose Study in Healthy Participants and Participants With an Autoimmune Disease
The main purpose of this study is to to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity of LAD191 in healthy adults and in adults with an autoimmune disease.
- Trial name
- NCT06488209
- Testing
- LAD191
- Where
- 3 sites in United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Almirall, S.A.
Plaque Psoriasis
A Study to Assess Treatment Satisfaction, Patient-reported Outcomes, Effectiveness, and Safety of a Fixed-dose Combination of Calcipotriene/Betamethasone Dipropionate PAD Cream in the Treatment of Mild-to-moderate Plaque Psoriasis of the Scalp in Adults
The main aim of this study is to assess treatment satisfaction, quality of life, treatment preference, adherence and convenience, psychosocial effects of scalp psoriasis, sleep quality, and effectiveness, and safety of…
- Trial name
- PRO-SCALP (NCT05811234)
- Testing
- CAL/BDP PAD Cream
- Where
- 37 sites in Germany, Spain and 1 more
- Volunteers
- 291 people
- Sponsor
- Almirall, S.A.
Plaque Psoriasis
A Study to Assess Patient-Reported Wellbeing Using Tildrakizumab in a Live Setting
The main purpose of this study to investigate the relationship between clinical symptoms and quality of life (QoL) in participants who receive Tildrakizumab in the frame of clinical routine for the treatment of moderate to severe…
- Trial name
- NCT06488170
- Testing
- Tildrakizumab
- Where
- 7 sites in Czechia
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Almirall, S.A.
Dermatitis, Atopic, Eczema
A Study of Lebrikizumab in Combination With Topical Corticosteroids in Patients With Atopic Dermatitis (AD) That Are Not Adequately Controlled With or Are Non-eligible for Cyclosporine
The main purpose of this study is to evaluate the efficacy of lebrikizumab compared with placebo in participants not adequately controlled with cyclosporine or for whom cyclosporine is not medically advisable up to Week 16.
- Trial name
- ADvantage (NCT05149313)
- Testing
- Lebrikizumab
- Where
- 48 sites in Austria, Belgium and 6 more
- Volunteers
- 331 people
- Sponsor
- Almirall, S.A.